You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (34) |
Back to Search
First-in-Human Studies of Monoclonal Antibodies in Oncology: An Overview of Study Designs and Stopping Criteria
- At: PSWC2020 (2020)
- Type: Poster
- By: LIANG, Man Qing (Université de Montréal, School of Public Health, Canada)
- Co-author(s): Man Qing Liang: École de santé publique de l’Université de Montréal, Université de Montréal, Montréal, Canada
Nathalie H Gosselin: Certara, Princeton, NJ, United States
Jean-François Marier: Certara, Princeton, NJ, United States - Abstract:
Background
First-in-human (FIH) trials for traditional cytotoxic molecules commonly use toxicity as the primary endpoint to determine the recommended dose for phase II studies. The promising research on monoclonal antibodies (mAbs) has prompted new dosing optimization approaches to emerge due to their different toxicity and pharmacokinetic profile.
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026